'Bluest of blue-chip in­vestors' pump $94M in­to Sekar Kathire­san's quest to bring CRISPR to the heart

Go­ing in­to his first JP Mor­gan con­fer­ence, Sekar Kathire­san had some ma­jor news to share. His am­bi­tious car­dio­vas­cu­lar-fo­cused start­up, Verve Ther­a­peu­tics, had des­ig­nat­ed the PC­SK9 base ed­i­tor as its lead pro­gram, homed in on se­vere het­erozy­gous fa­mil­ial hy­per­c­ho­les­terolemia as the first in­di­ca­tion, and re­leased an­i­mal da­ta sug­gest­ing the in vi­vo ed­its to the mon­key liv­ers last up to six months. For a com­pa­ny that had just been in the pub­lic for less than a year, “it was won­der­ful.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER